Transient arrest in a quiescent state allows ovarian cancer cells to survive suboptimal growth conditions and is mediated by both Mirk/dyrk1b and p130/RB2

International Journal of Cancer

Volumn 129, Issue 2, 2011, Pages 307-318

  Hu, Jing ^a   Nakhla, Hassan ^a   Friedman, Eileen ^a  

^a State University of New York Upstate Medical University: College of Medicine   (United States)

Author keywords

Mirk dyrk1B; Ovarian cancer; Quiescence

Indexed keywords

BIOLOGICAL MARKER; CYCLIN D1; PROTEIN MIRK; PROTEIN P130; PROTEIN SERINE THREONINE KINASE; TRANSCRIPTION FACTOR E2F4; UNCLASSIFIED DRUG; DYRK KINASE; PROTEIN TYROSINE KINASE; RBL2 PROTEIN, HUMAN; TUMOR PROTEIN;

ADULT; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CELL COUNT; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL SURVIVAL; CELL VIABILITY; COMPLEX FORMATION; CONTROLLED STUDY; CULTURE MEDIUM; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; MIRK GENE; OVARY CANCER; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN FUNCTION; REGULATOR GENE; ADENOCARCINOMA; METABOLISM; OVARY TUMOR; PATHOLOGY; PHYSIOLOGY; TUMOR CELL LINE;

ADENOCARCINOMA; CELL LINE, TUMOR; CELL SURVIVAL; FEMALE; G0 PHASE; HUMANS; NEOPLASM PROTEINS; OVARIAN NEOPLASMS; PROTEIN-SERINE-THREONINE KINASES; PROTEIN-TYROSINE KINASES; RETINOBLASTOMA-LIKE PROTEIN P130;

EID: 79961121875     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.25692     Document Type: Article

References (49)

1. Deng X, Mercer SE, Shah S, Ewton DZ, Friedman E. The Cyclin-dependent Kinase Inhibitor p27Kip1 Is Stabilized in G0 by Mirk/dyrk1B Kinase. J Biol Chem 2004;279: 22498-504. (Pubitemid 38679449)
2. Besson A, Gurian-West M, Chen X, Kelly-Spratt KS, Kemp CJ, Roberts JM. A pathway in quiescent cells that controls p27Kip1 stability, subcellular localization, and tumor suppression. Genes Dev 2006;20: 47-64. (Pubitemid 43042667)
3. Janumyan Y, Cui Q, Yan L, Sansam CG, Vanlentin M, Yang E. G0 function of BCL2 and BCL-xL requires BAX, BAK, and p27 phosphorylation by Mirk, revealing a novel role of BAX and BAK in quiescence regulation. J Biol Chem 2008; 283:34108-20.
4. Sang L, Coller HA, Roberts JM. Control of the reversibility of cellular quiescence by the transcriptional repressor HES1. Science 2008;321:1095-100.
5. Sang L, Roberts JM, Coller HA. Hijacking HES1: How tumors co-opt the antidifferentiation strategies of quiescent cells. Trends Mol Med 2010;16:17.
6. Barnes D, Melo J. Primitive, quiescent and difficult to kill: The role of nonproliferating stem cells in chronic myeloid leukemia. Cell Cycle 2006;5:2862-6. (Pubitemid 44953936)
7. Deng X, Ewton DZ, Friedman E. Mirk/ Dyrk1B maintains the viability of quiescent pancreatic cancer cells by decreasing ROS levels. Cancer Res 2009;69:3317-24.
8. Schindlbeck C, Hantschmann P, Zerzer M, Jahns B, Rjosk D, Janni W, Rack, B Sommer H, Friese K. Prognostic impact of KI67, p53, human epithelial growth factor receptor 2, topoisomerase IIalpha, epidermal growth factor receptor, and nm23 expression of ovarian carcinomas and disseminated tumor cells in the bone marrow. Int J Gynecol Cancer 2007;17: 1047-55. (Pubitemid 47414831)
9. Kusumbe AP, Bapat SA. Cancer stem cells and aneuploid populations within developing tumors are the major determinants of tumor dormancy. Cancer Res 2009;69:9245-53.
10. Lu Z, Luo R, Lu Y, Zhang X, Yu Q, Khare S, Kondo S, Kondo Y, Yu, Y. Mills GB, Liao S-L, Bast RC, Jr The tumor suppressor gene ARHI regulates autophagy and tumor dormancy in human ovarian cancer cells. J Clin Invest 2008;118: 3917-29.
11. Amaravadi RK. Autophagy-induced tumor dormancy in ovarian cancer. J Clin Invest 2008;118:3837-40.
12. Adam AP, George A, Schewe D, Bragado P, Iglesias BV, Ranganathan AC, Kourtidis A, Conklin DS, Aguirre-Ghiso JA. Computational identification of a p38SAPK-regulated transcription factor network required for tumor cell quiescence. Cancer Res 2009;69:5664-72.
13. Chen C, Liu Y, Liu R, Ikenoue T, Guan K-L, Liu Y, Zheng P. TSC-mTOR maintains quiescence and function of hematopoietic stem cells by repressing mitochondrial biogenesis and reactive oxygen species. J Exp Med 2008;205:2397-408.
14. Jin K, Park S-J, Ewton D, Friedman E. The survival kinase Mirk/dyrk1B is a downstream effector of oncogenic K-ras. Cancer Res 2007;67:7247-55. (Pubitemid 47206553)
15. Tejedor F, Zhu X, Kaltenbach E, Ackermann A, Baumann A, Canal I, Heisenberg M, Fischbach KF, Pongs O. Minibrain:a new protein kinase family involved in postembryonic neurogenesis in Drosophila. Neuron 1995;14: 287-301.
16. Kentrup H, Becker W, Heukelbach J, Wilmes A, Schurman A, Huppertz C, Kainulainen H, Joost H-G. Dyrk, a dual specificity protein kinase with unique structural features whose activity is dependent on tyrosine residues between subdomains VII and VIII. J Biol Chem 1996;271:3488-95. (Pubitemid 26065657)
17. Becker W, Weber Y, Wetzel K, Eirmbter K, Tejedor F, Joost H-G. Sequence characteristics, subcellular localization and substrate specificity of dyrk-related kinases, a novel family of dual specificity protein kinases. J Biol Chem 1998;273:25893-902. (Pubitemid 28475820)
18. Mercer SE, Ewton DZ, Deng X, Lim S, Mazur TR, Friedman E. Mirk/Dyrk1B Mediates Survival during the Differentiation of C2C12 Myoblasts. J Biol Chem 2005;280:25788-801. (Pubitemid 40962289)
19. Arron JR, Winslow MM, Polleri A, Chang C-P, Wu H, Gao X, Neilson JR, Chen L, Heit JJ, Kim SK, Yamasaki N, Miyakawa T, Francke U, Graef IA, Crabtree GR. NFAT dysregulation by increased dosage of DSCR1 and DYRK1A on chromosome 21. Nature 2006;441:595-600. (Pubitemid 43927286)
20. Geiger JN, Knudsen GT, Panek L, Pandit AK, Yoder MD, Lord KA, Creasy CL, Burns BM, Gaines P, Dillon SB, Wojchowski DM. mDYRK3 kinase is expressed selectively in late erythroid progenitor cells and attenuates colonyforming unit-erythroid development. Blood 2001;97:901-10. (Pubitemid 32154272)
21. Li K, Zhao S, Karur V, Wojchowski DM. DYRK3 activation, engagement of protein kinase A/cAMP response element-binding protein, and modulation of progenitor cell survival. J Biol Chem 2002;277:47052-60. (Pubitemid 36159213)
22. Sacher F, Moller C, Bone W, Gottwald U, Fritsch M. The expression of the testisspecific Dyrk4 kinase is highly restricted to step 8 spermatids but is not required for male fertility in mice. Mol Cell Endocrinol 2007;267:80-8.
23. Gwack Y, Sharma S, Nardone J, Tanasa B, Iuga A, Srikanth S, Okamura H, Bolton D, Feske S, Hogan PG, Rao A. A genomewide Drosophila RNAi screen identifies DYRK-family kinases as regulators of NFAT. Nature 2006;441:646.
24. Leder S, Czajkowska H, Maenz B, de Graaf K, Barthel A, Joost H-G, Becker W. Alternative splicing variants of the protein kinase DYRK1B exhibit distinct patterns of expression and functional properties. Biochem J 2003;372:881-8. (Pubitemid 36760401)
25. Collins CS, Hong J, Sapinoso L, Zhou Y, Liu Z, Micklash K, Schultz, PG, Hampton G. A small interfering RNA screen for modulators of tumor cell motility identifies MAP4K4 as a promigratory kinase. PNAS 2006;103:3775-80. (Pubitemid 43376631)
26. Lee K, Deng X, Friedman E. Mirk protein kinase is a mitogen-activated protein kinase substrate that mediates survival of colon cancer cells. Cancer Res 2000;60: 3631-37. (Pubitemid 30482186)
27. Mercer SE, Ewton DZ, Shah S, Naqvi A, Friedman E. Mirk/Dyrk1b mediates cell survival in rhabdomyosarcomas. Cancer Res 2006;66:5143-50. (Pubitemid 43844936)
28. Deng X, Ewton DZ, Li S, Naqvi A, Mercer SE, Landas S, Friedman E. The kinase Mirk/Dyrk1B mediates cell survival in pancreatic ductal adenocarcinoma. Cancer Res 2006;66:4149-58.
29. Deng X, Ewton DZ, Mercer SE, Friedman E. Mirk/dyrk1B decreases the nuclear accumulation of class II histone deacetylases during skeletal muscle differentiation. J Biol Chem 2005;280: 4894-905. (Pubitemid 40288664)
30. Coller H, Sang L, Roberts JM. A new description of cellular quiescence. PLOS Biol 2006;4:329-49.
31. D'Andrilli G, Masciullo V, Bagella L, Tonini T, Minimo C, Zannoni GF, Giuntoli RL, II, Carlson JA, Jr, Soprano DR, Soprano KJ, Scambia G, Giordano A. Frequent loss of pRb2/p130 in human ovarian carcinoma. Clin Cancer Res 2004; 10:3098-103. (Pubitemid 38619689)
32. Smith E, Leone G, Nevins J. Distinct mechanisms control the accumulation of the Rb-related p107 and p130 proteins during cell growth. Cell Growth Differ 1998;9:297-303. (Pubitemid 28345883)
33. Kops GJPL, Dansen TB, Polderman PE, Saarloos I, Wirtz KWA, Coffer PJ, Lam EW, Burgering F, Boudewijn MT. Forkhead transcription factor FOXO3a protects quiescent cells from oxidative stress. Nature 2002;419:316.
34. Canhoto A, Chestukhin A, Litovchick L, DeCaprio JA. Phosphorylation of the retinoblastoma-related protein p130 in growth-arrested cells. Oncogene 2000;19: 5116-22.
35. Farkas T, Hansen K, Holm K, Lukas J, Bartek J. Distinct phosphorylation events regulate p130-and p107-mediated repression of E2F-4. J Biol Chem 2002;277: 26741-52. (Pubitemid 34951678)
36. Smith EJ, Leone G, DeGregori J, Jakoi L, Nevins JR. The accumulation of an E2Fp130 transcriptional repressor distinguishes a G0 cell state from a G1 cell state. Mol Cell Biol 1996;16:6965-76. (Pubitemid 26389756)
37. Deng X, Ewton DZ, Pawlikowski B, Maimone M, Friedman E. Mirk/dyrk1B is a Rho-induced kinase active in skeletal muscle differentiation. J Biol Chem 2003; 278:41347-54. (Pubitemid 37280964)
38. Jin K, Ewton D, Park S, Hu J, Friedman E. Mirk regulates the exit of colon cancer cells from quiescence. J Biol Chem 2009; 284:22916-25.
39. Zou Y, Ewton D, Deng D, Mercer S, Friedman E. Mirk/dyrk1B kinase destabilizes cyclin D1 by phosphorylation at threonine 288. J Biol Chem 2004;279: 27790-98. (Pubitemid 38812621)
40. Thompson FH, Nelson MA, Trent JM, Guan X-Y, Liu Y, Yang J-M, Emerson J, Adair L, Wymer J, Balfour C, Massey K, Weinstein R, Alberts DS, Taetle R. Amplification of 19q13.1-q13.2 sequences in ovarian cancer: G-band, FISH, and molecular studies. Cancer Genet Cytogenet 1996;87:55.
41. Karhu R, Mahlamaki E, Kallioniemi A. Pancreatic adenocarcinoma-genetic portrait from chromosomes to microarrays. Genes Chromosomes Cancer 2006;45: 721-30.
42. Moniaux N, Nemos C, Schmied BM, Chauhan SC, Deb S, Morikane K, Choudhury A, VanLith M, Sutherlin M, Sikela JM, Hollingsworth MA, Batra SK. The human homologue of the RNA polymerase II-associated factor 1 (hPaf1), localized on the 19q13 amplicon, is associated with tumorigenesis. Oncogene 2006;25:3247-57. (Pubitemid 43846309)
43. Kuuselo R, Savinainen K, Azorsa DO, Basu GD, Karhu R, Tuzmen S, Mousses S, Kallioniemi A. Intersex-like (IXL) is a cell survival regulator in pancreatic cancer with 19q13 amplification. Cancer Res 2007;67: 1943-49. (Pubitemid 46424210)
44. Cheng J, Godwin A, Bellacosa A, Taguchi T, Franke T, Hamilton T, Tsichlis PN, Testa JR. AKT2, a putative oncogene encoding a member of a subfamily of protein-serine/threonine kinases, is amplified in human ovarian carcinomas. PNAS 1992;89:9267-71.
45. Hu J, Friedman E. Mirk kinase is a novel factor mediating cisplatin resistance in ovarian cancer cells. Genes Cancer, in press.
46. Moreno CS, Matyunina L, Dickerson EB, Schubert N, Bowen NJ, Logani S, Benigno BB, McDonald JF. Evidence that p53 mediated cell-cycle-arrest inhibits chemotherapeutic treatment of ovarian carcinomas. PLoS ONE 2007;2: E441.
47. Shaw RJ. LKB1 and AMP-activated protein kinase control of mTOR signalling and growth. Acta Physiol 2009;196:65-80.
48. Soprano KJ, Purev E, Vuocolo S, Soprano DR. Rb2/p130 and protein phosphatase 2A: Key mediators of ovarian carcinoma cell growth suppression by all-trans retinoic acid. Oncogene 2006;25:5315.
49. Litovchick L, Sadasivam S, Florens L, Zhu X, Swanson SK, Velmurugan S, Chestukhin A, DeCaprio JA. Evolutionarily conserved multisubunit RBL2/p130 and E2F4 protein complex represses human cell cycledependent genes in quiescence. Mol Cell 2007;26:539.